Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
  • Policy / Pricing

List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

Drug Channels

This week, I'm rerunning some popular posts while we prepare for Friday's live video webinar: PBM Industry Update 2026: Trends, Challenges, and What's Ahead .

Policy / PricingRead full story

pharminent April 8, 2026 (Last updated: April 8, 2026)

Drug Channels

This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .

Policy / PricingRead full story

Post navigation

Previous: EU invests 30m to fight antimicrobial resistance
Next: Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.